Elevated body mass index predicts for longer overall survival duration in men with metastatic hormone-refractory prostate cancer

Related Experiment Video

Updated: Aug 18, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Susan Halabi, Eric J Small, Nicholas J Vogelzang

    Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
    |April 1, 2005
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    An Orthotopic Murine Model of Human Prostate Cancer Metastasis
    06:48

    An Orthotopic Murine Model of Human Prostate Cancer Metastasis

    Published on: September 18, 2013

    Related Experiment Videos

    Last Updated: Aug 18, 2026

    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
    07:25

    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

    Published on: March 6, 2018

    An Orthotopic Murine Model of Human Prostate Cancer Metastasis
    06:48

    An Orthotopic Murine Model of Human Prostate Cancer Metastasis

    Published on: September 18, 2013

    Related Concept Videos

    Cancer Survival Analysis01:21

    Cancer Survival Analysis

    Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
    Kaplan-Meier Approach01:24

    Kaplan-Meier Approach

    The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...

    Articles linked to this work by shared authors, journal, and citation graph.

    Management of Patients with High-risk Localised, Locally Advanced, and Biochemically Recurrent Prostate Cancer: Report from the 2026 Advanced Prostate Cancer Consensus Conference.

    European urology·2026

    External validation of the NADIR model for early prostate-specific antigen response prediction in enzalutamide-treated metastatic hormone-sensitive prostate cancer: An analysis of the ARCHES trial.

    Cancer·2026

    Convergent evolution of complex structural variants drives therapy resistance in metastatic prostate cancer.

    Genome biology·2026

    Association of race and survival in patients treated with apalutamide: Pooled analysis of two phase 3 trials.

    Cancer·2025

    A roadmap for future clinical research in advanced prostate cancer: Findings from the Advanced Prostate Cancer Consensus Conference (APCCC) 2024.

    European journal of cancer (Oxford, England : 1990)·2025

    Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancer.

    Nature communications·2025

    Darovasertib and Crizotinib First-Line Treatment for Metastatic Uveal Melanoma: Overall Survival, Efficacy, and Safety From the OptimUM-01 Study.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    KEYNOTE-867: A Phase III, Randomized, Double-Blind Study of Stereotactic Body Radiotherapy With Pembrolizumab for Unresected Stage I or II Non-Small Cell Lung Cancer.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    PARP Inhibitors in the Management of Ovarian Cancer: ASCO Living Guideline, Version 2026.1.0.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Art as a Shared Space: Tracing the Unseen Through a Body Map.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Dalmelitinib Plus Aumolertinib in Advanced NSCLC Patients With EGFR-TKI Resistance and MET Amplification: A Randomized Phase 3 Trial.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    ENZARAD (ANZUP 1303): Phase 3 Trial of Enzalutamide With Androgen Deprivation Therapy and Radiation Therapy in High-Risk Localized or Locally Advanced Prostate Cancer.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Predicting recurrence risk after neoadjuvant therapy in breast cancer: a single-center retrospective cohort study integrating residual cancer burden and immune microenvironment features.

    Frontiers in oncology·2026

    Prognostic associations of PD-L1 expression and BAP1 loss in pleural mesothelioma: a retrospective single-center cohort from Colombia.

    Frontiers in oncology·2026

    Multiparametric MRI radiomics for preoperative prediction of tumor budding grade in rectal cancer.

    Frontiers in oncology·2026

    IVIM-based habitat imaging for non-invasive assessment of Ki-67 proliferation status in cervical cancer.

    Frontiers in oncology·2026

    Diagnostic performance of next-generation sequencing in thyroid nodules and molecular correlates of tumor aggressiveness in papillary thyroid carcinoma.

    Frontiers in endocrinology·2026

    Multimodal radiomics based on dynamic contrast-enhanced ultrasound for predicting cervical lymph node metastasis in papillary thyroid carcinoma with Hashimoto's thyroiditis.

    Frontiers in oncology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us